公开(公告)号：US20210246137A1

公开(公告)日：2021-08-12

申请号：US17237351

申请日：2021-04-22

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US20190315740A1

公开(公告)日：2019-10-17

申请号：US16341000

申请日：2017-10-13

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61P33/06 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US10988472B2

公开(公告)日：2021-04-27

申请号：US16341000

申请日：2017-10-13

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/06 ,  A61K31/4745 ,  C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US11753408B2

公开(公告)日：2023-09-12

申请号：US17237351

申请日：2021-04-22

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/14 ,  A61K31/4375 ,  C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II):




wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US20210188843A1

公开(公告)日：2021-06-24

申请号：US17054614

申请日：2019-05-13

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

发明人： Wenwei Huang ,  Hao Li ,  Wei Zheng ,  Wei Sun ,  Xiuli Huang ,  Xiao Lu ,  Philip E. Sanderson ,  Xin Xu ,  Pranav Shah ,  Kim C. Williamson ,  Zhiji Luo ,  Gregory J. Tawa

IPC分类号： C07D471/04 ,  A61P33/06 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) wherein R1, R2, R3, A, and B are as defined herein, and a method of preparing such compounds. Also disclosed are pharmaceutical compositions containing the compound of formula (I) and a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria by killing or arresting the growth of Plasmodium organisms in a mammal, wherein the Plasmodium organisms are in a liver stage, an asexual stage, or gametocytes, comprising administering to an animal an effective amount of a compound of formula (I).